Abstracts Archive - Page 731 of 2425 - ACR Meeting Abstracts

Abstract Number: 1557 • ACR Convergence 2020
Lymphatics as a Biomarker of Joint Physiology: Near-Infrared Imaging of Indocyanine Green Identifies Novel Routes of Lymphatic Drainage from Metacarpophalangeal Joints in Healthy Human Hands
H. Mark Kenney¹, Gregory Dieudonne¹, Ronald Wood¹, Edward Schwarz¹, Christopher Ritchlin² and Homaira Rahimi³, ¹University of Rochester Medical Center, Rochester, ²Department of Medicine, University of Rochester Medical Center, Rochester, NY, ³University of Rochester Medical Center, Rochester, NY
Background/Purpose: In our previous work, we discovered that patients with active hand RA have reduced lymphatic drainage of indocyanine green (ICG) from the web spaces…
Abstract Number: 1556 • ACR Convergence 2020
Assessing Calcinosis in Dermatomyositis with Computed Tomography and Calcium Scoring
Prateek Gowda¹, Briana Cervantes², Lisa G. Rider³, Frederick W. Miller⁴, Marcus Chen⁴ and Adam Schiffenbauer⁴, ¹NIBIB, Baltimore, MD, ²NIEHS, Silver Spring, MD, ³Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD, ⁴National Institutes of Health, Bethesda, MD
Background/Purpose: Calcinosis is a condition in which calcium salts are deposited in and around soft tissue and is observed in up to 30% of adult…
Abstract Number: 1562 • ACR Convergence 2020
Subclinical Joint Inflammation of Hands by Magnetic Resonance Imaging in Patients with Psoriatic Arthritis in Clinical Remission Compared to Active Disease
Victoria Furer¹, Ari Polachek², David Levartovsky¹, Jonathan Wollman³, Mirna Zureik³, Daphna Paran¹, Hagit Sarbagil-Maman⁴, Sara Borok Lev-Ran¹, Mark Berman¹, Ilana Kaufman⁵, Adi Broide³, Valerie Aloush¹, Yael Lahat goldstein¹, Sharon Nevo³, Iris Eshed⁶ and Ori Elkayam³, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Tel Aviv Sourasky Medical Center, Petah-Tikva, Israel, ³Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel, ⁴Tel-Aviv Sourasky Medical Center, Kiryat Ono, Israel, ⁵Tel Aviv Sourasky Medical Center, Petah-Tiqwa, Israel, ⁶Sheba Medical Center, Tel-Aviv, Israel
Background/Purpose: Assessment of disease activity in psoriatic arthritis (PsA) is based on tender and swollen joint counts (TJC and SJC, respectively). Yet, the prevalence of…
Abstract Number: 1564 • ACR Convergence 2020
Feasibility of Ultra-low-dose, Short-duration, Total-body Evaluation of Inflammatory Arthritis Using uEXPLORER 18F-FDG PET/CT
Soumajyoti Sarkar¹, Siba Raychaudhuri², Lorenzo Nardo³, Heather Hunt³, Denise Caudle⁴, Mike Nguyen⁴, Simon Cherry⁴, Ramsey Badawi⁴, Abhijit Chaudhari⁵ and Yasser Abdelhafez³, ¹University of California, Davis, Davis, ²Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, and VA Medical Center Sacramento, Sacramento, CA, ³University of California Davis, Sacramento, CA, ⁴University of California Davis, Sacramento, ⁵University of California, Davis, Sacramento, CA
Background/Purpose: The uEXPLORER system enables the unique, simultaneous acquisition of PET data over the entire adult human body with a high-sensitivity, alongside concurrent CT data.…
Abstract Number: 1559 • ACR Convergence 2020
Fully Automatic Assessment of Nail Fold Capillaroscopy Software – Early Results
Olga Brzezińska¹, Krzysztof Rychlicki-Kicior² and Joanna Makowska¹, ¹Department of Rheumatology, Medical University of Lodz, Poland, Lodz, Lodzkie, Poland, ²University of Economics and Human Sciences in Warsaw, Poland, Lodz, Poland
Background/Purpose: Changes in capillaroscopy nailfold image are a valuable element in the diagnostic procedure and monitoring of systemic sclerosis as well as other systemic diseases.…
Abstract Number: 1554 • ACR Convergence 2020
Response to Tocilizumab in Large Vessel Vasculitis According to the Extent of Baseline 18F-FDG Vascular Uptake
Lara Sanchez-Bilbao¹, Diana Prieto-Peña², Inigo Gonzalez-Mazon³, David Martinez-Lopez⁴, Monica Calderon-Goercke⁵, Isabel Martínez-Rodríguez⁵, Ignacio Banzo⁵, Miguel Ángel González-Gay⁶ and Ricardo Blanco¹, ¹Hospital Universitario Marques de Valdecilla, Santander, Spain, ²Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁶Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: 18F-fluodeoxyglucose positron emission tomography (18F-FDG PET/CT) is useful to establish the presence and extent of large vessel vasculitis (LVV). Tocilizumab (TCZ) has shown efficacy…
Abstract Number: 1567 • ACR Convergence 2020
Association of Blood Count Biomarkers and Clinical Features with Immune Related Adverse Events (irAEs) in Patients with Cancer Treated with Checkpoint Inhibitors (CPI)
Despina Michailidou¹, Ali R Khaki², Guangyu Wang³, Leonidas Diamantopoulos² and Petros Grivas², ¹Division of Rheumatology, University of Washington, Seattle, Washington, Seattle, WA, ²Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, Seattle, WA, ³Department of Biostatistics, University of Washington, Seattle, Washington, Seattle, WA
Background/Purpose: Patients with cancer treated with CPI can develop irAEs. Since immune changes may impact blood counts and ratios, we hypothesized that those would be…
Abstract Number: 1570 • ACR Convergence 2020
Immune Checkpoint Inhibitor Treatment in Cancer: Immunomodulator Use and Evaluation by Rheumatology
Amy Cunningham-Bussel¹, Jiaqi Wang¹, Lauren C. Prisco², Lily Martin², Lydia Gedmintas¹, Lindsey Macfarlane¹, Nancy Shadick¹, Mark Awad³, Osama Rahma³, Nicole LeBoeuf³, Ellen Gravallese¹ and Jeffrey Sparks¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Dana-Farber Cancer Institute, Boston, MA
Background/Purpose: Immune checkpoint inhibitors (ICI) are used to treat an expanding number of cancers. Many cancer patients treated with ICI develop immune-related adverse events (irAE)…
Abstract Number: 1571 • ACR Convergence 2020
Distinct T Cell Responses in Inflammatory Arthritis Associated with Combined CTLA-4 and PD-1 Inhibitor Therapy
Sang Kim¹, Jean Tayar², Maria Suarez-Almazor³, Huifang Lu⁴, Yang-Zhi Zhao⁵, Margarita Divenko⁵, William Padron⁵, Emma Rodriguez⁵, Sattva Neelapu⁵, Jennifer Wang⁵, Amish Shah⁵, Nizar Tannir⁵, Don Gibbons⁵, Guillermo Garcia-Manero⁵, Hussein Tawbi⁵, Patrick Hwu⁵, Andrew Futreal⁵, Adi Diab⁵ and Roza Nurieva⁵, ¹The Univesrity of Texas MD Andesron Cancer Center, Pearland, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³University of Texas MD Anderson Cancer Center, Houston, TX, ⁴MD Anderson, Houston, TX, ⁵MD Anderson, Houston
Background/Purpose: Despite of unprecedented clinical success in cancer therapeutics, immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Arthritis-irAE can…
Abstract Number: 1566 • ACR Convergence 2020
Onset and Disease Course of Inflammatory Arthritis in Patients Receiving Immune Checkpoint Inhibitor Therapy at a Single Institution
Christina Boutsicaris¹, Angelo Ciliberti², Elizabeth Lockerman¹, Faizah Siddique³ and Rochella Ostrowski¹, ¹Loyola University Medical Center, Maywood, IL, ²Loyola University Medical Center, Oak Park, IL, ³Loyola University Medical Center, Lombard, IL
Background/Purpose: Immune checkpoint inhibitors (ICI) have improved outcomes for many types of cancer, but the therapy is known to cause immune-related adverse events (IRAE). ICI…
Abstract Number: 1577 • ACR Convergence 2020
Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis
Jeffrey Sarazin¹, Ann Impens², Nada Abdulaziz¹, Stacey Anderson³, Leslie Fecher¹, Christopher Lao¹ and Elena Schiopu¹, ¹Michigan Medicine, Ann Arbor, MI, ²Midwestern University, Ann Arbor, IL, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as a paradigm shift in the treatment of malignancies, but can have significant side effects, termed immune related…
Abstract Number: 1574 • ACR Convergence 2020
Over Half of Patients with Immune Checkpoint Inhibitor-related Myositis, Myasthenia Gravis and/or Myocarditis Have Autoantibodies: Results from a Systematic Literature Review
Nilasha Ghosh¹, Karmela Kim Chan², Bridget Jivanelli³ and Anne Bass¹, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital For Special Surgery, New York, NY, ³Hospital for Special Surgery, New York
Background/Purpose: Although immune checkpoint inhibitor (ICI) cancer treatments are known to activate cytotoxic T-cells, autoantibodies may also contribute to the development of immune-related adverse events…
Abstract Number: 1569 • ACR Convergence 2020
Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center
Bushra Akram¹, Aleena Itani¹, Mohammad Razaq², Samera Vaseer¹, Sara Vesely¹ and Pawan Acharya¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Immune check point inhibitors (ICIs) allow the body to recognize tumor cells as non-self, resulting in immune-cell mediated tumor cell destruction. These therapies have the…
Abstract Number: 1461 • ACR Convergence 2020
Implementation, Feasibility and Acceptability of Take Charge, an Email Series to Increase Knowledge of Lupus Self-Management Skills
Karin Tse¹, Mary Crimmings², Mike Donnelly², Reid Dossinger², Lauren Metelski² and Latifa Boyce², ¹Lupus Foundation of America, DC, WA, ²Lupus Foundation of America, WASHINGTON, DC
Background/Purpose: The Lupus Foundation of America developed and launched an educational email series, Take Charge, to provide people with lupus educational information, tools and resources…
Abstract Number: 1336 • ACR Convergence 2020
Bone Mineral Density, Trabecular Bone Score and Proximal Femur 3D-DXA Analysis in Psoriatic Diseases
Eric Toussirot¹, Renaud Winzenrieth², Maxime Desmarets³, Daniel Wendling⁴, Francois Aubin⁵ and Gilles Dumoulin⁶, ¹CIC biotherapies, Besançon University Hospital, Besançon, France, ²GALGO medical, Barcelona, Spain, ³INSERM CIC-1431, Besancon, France, ⁴CHU Besançon, department of rheumatology, Besancon, France, ⁵Dermatology, Besancon, France, ⁶Laboratoire de Biochimie Médicale, UF de Biochimie Endocrinienne et Métabolique, Besancon, France
Background/Purpose: current data regarding areal bone mineral density (aBMD) in patients with psoriasis (PsO) or psoriatic arthritis (PsA) are conflicting. Results on Trabecular Bone Score…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].